✦ LIBER ✦

Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa

✍ Scribed by Takeaki Suou; Keiko Hosho; Yukihiro Kishimoto; Yasushi Horie; Hironaka Kawasaki

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 618 KB
Volume: 22
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840220209

No coin nor oath required. For personal study only.

✦ Synopsis

To evaluate the effect of interferon alfa (EN-a) on the hepatic extracellular matrix, we investigated the changes in serum N-terminal propeptide of type I11 procollagen during and after 4 months of INF-ru treatment in 178 treated and 45 nontreated patients with chronic hepatitis C. Serum pretreatment levels in nonresponders were significantly higher than those in long-term and short-term responders, but those levels were not different in the latter two groups. Serum propeptide levels decreased significantly during and after IFN-ru therapy in the treated patients, although those levels were unchanged in the nontreated patients. This decrease was sustained for 12 months after IFN-ru was completed not only in long-but also in short-term responders and nonresponders. Serum propeptide levels decreased in those with elevated pretreatment levels, but not in those with normal initial levels, whereas serum transaminase levels decreased similarly in both groups. The changes in serum propeptide levels during and after treatment were more closely correlated with the initial levels compared with those in serum transaminase levels. These results suggested that IFN-ru treatment induces the long-term suppression of active fibrogenesis in chronic hepatitis C independent of antiviral and anti-necroinflammatory effects, thus preventing progression to cirrhosis. (HEPA-TOLOGY 199622~426-431.)

Hepatitis C virus (HCV) is a positive-stranded RNA virus responsible for most non-A, non-B hepatitis. Chronic hepatitis C is rarely spontaneously resolved, and most cases progress to liver cirrhosis and hepatocellular carcinoma.ls2 Treatment with interferon alfa (IFN-a) is effective for decreasing serum alanine aminotransferase (ALT) levels, improving hepatocellular

📜 SIMILAR VOLUMES

Long-Term Follow-Up of Serum N-Terminal

Long-Term Follow-Up of Serum N-Terminal Propeptide of Collagen Type III Levels in Patients with Chronic Liver Disease

✍ Kurt Weigand; Pierre-Yves Zaugg; Alain Frei; Arthur Zimmermann 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views

To evaluate the diagnostic and prognostic significance of the N-terminal propeptide of collagen Type III (Col 1-3) in chronic liver disease, the peptide level was measured in the serum of 4 patients with primary biliary cirrhosis, 5 with chronic persistent hepatitis, 12 with chronic active hepatitis

Serum levels of hepatitis C virus core p

Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa

✍ E Tanaka; K Kiyosawa; A Matsumoto; T Kashiwakuma; A Hasegawa; H Mori; O Yanagiha 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

The quantitation of hepatitis C virus (HCV) viremia RNA is measured by molecular techniques such as comcan be helpful in the diagnosis, therapy, and monitoring petitive reverse-transcription polymerase chain reacof patients with chronic hepatitis C. A sensitive and tion and branched DNA (bDNA) signa

Quantitation and typing of serum hepatit

Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-β

✍ Yoshinao Kobayashi; Shozo Watanabe; Masayoshi Konishi; Masato Yokoi; Ryuichi Kak 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 646 KB

We quantified serum hepatitis C virus RNA titers and determined hepatltis C virus subtypes in chronic hepatitis C patients treated with interferon$ to investigate relationships among serum ALT response, serum hepatitis C virus titer and hepatitis C virus subtype. Of 146 chronic hepatitis C patients

The N-Terminal Propeptide of Collagen Ty

The N-Terminal Propeptide of Collagen Type III in Serum Reflects Activity and Degree of Fibrosis in Patients with Chronic Liver Disease

✍ Alain Frei; Arthur Zimmermann; Kurt Weigand 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 592 KB

To evaluate the diagnostic significance of the collagen Type I11 (Col 1-3) N-terminal propeptide of procollagen Type 111, with respect to activity and degree of liver fibrosis, Col 1-3 serum concentrations were measured in 11 1 patients with chronic liver diseases and in 60 patients were correlated

Comparison of HCV RNA assays for the det

Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon

✍ Trabaud, M.-A.; Bailly, F.; Si-Ahmed, S. N.; Chevallier, P.; Sepetjan, M.; Coluc 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

Detection and quantification of hepatitis C virus (HCV) RNA levels by using the standardized qualitative Amplicor™ HCV and quantitative Amplicor HCV Monitor™ assays (Roche Molecular Systems) were evaluated in 48 patients with chronic hepatitis C treated with interferon. Results were compared with an

Lymphoblastoid interferon alfa-n1 improv

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial

✍ Geoffrey C. Farrell; Bruce R. Bacon; Robert D. Goldin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

The aim of this study was to compare the short-term and long-term efficacy and safety of lymphoblastoid interferon with a recombinant interferon alfa (IFN-␣) in a 24-week treatment course for chronic hepatitis C. One thousand seventy-one patients with chronic hepatitis C were randomized to receive l